New radiation boost aims to zap prostate tumors harder, faster

NCT ID NCT07325721

Recruiting now Disease control Sponsor: Medical University of South Carolina Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a new radiation approach for men with high-risk or locally advanced prostate cancer. It combines hypofractionated radiotherapy (fewer, larger doses) with a microboost that delivers extra radiation to the most aggressive tumor spots. The goal is to improve cancer control while keeping side effects manageable. About 46 men will receive 25 radiation sessions along with standard hormone therapy, and researchers will track urinary and bowel side effects, PSA levels, and quality of life for up to 5 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hypofractionated radiation therapy with a focal microboost
What this could lead to: If successful, this approach could offer a more effective and convenient radiation treatment for high-risk prostate cancer, potentially improving tumor control without increasing side effects.
What could go wrong: This is a small, early-phase trial with only 46 participants, so results may not apply to all patients. The higher radiation dose could increase urinary or bowel side effects, and long-term benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH RISK PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER PROSTATE CANCER PATIENTS TREATED BY RADIOTHERAPY

Contacts and locations

Locations

Medical University of South Carolina Hollings Cancer Center
RECRUITING

Charleston, South Carolina, 29425, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.